Enovis Corporation
Rank #168StartupENOV · NYSE · Healthcare
Enovis Corporation (ENOV) — Rank #168 by gross profitability (GP/assets 0.36) · ROE -80.2% · Piotroski F-Score 4 / 9.
As-of 2026-09-15 · CIK 0001420800 · all metrics point-in-time as of the filing date.
About
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally.
Show moreShow less
It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation.
Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- enovis.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-26 | 2024-12-31filed 2025-02-26 | 2023-12-31filed 2024-02-22 | 2022-12-31filed 2023-03-01 |
|---|---|---|---|---|
| Assets | ||||
| Cash & equivalents | 36.4 | 48.2 | 36.2 | 24.3 |
| Short-term investments | — | — | — | — |
| Accounts receivable | 442.8 | 407.0 | 291.5 | 267.4 |
| Inventory | 584.4 | 547.1 | 468.8 | 426.6 |
| Total current assets | 1,207.1 | 1,146.4 | 896.5 | 795.0 |
| Property, plant & equipment, net | 507.1 | 404.5 | 270.8 | 236.7 |
| Goodwill | 718.3 | 1,692.7 | 2,060.9 | 1,983.6 |
| Intangible assets (excl. goodwill) | 1,236.7 | 1,317.4 | 1,127.4 | 1,110.7 |
| Total assets | 3,834.7 | 4,718.8 | 4,509.3 | 4,273.2 |
| Liabilities | ||||
| Accounts payable | 187.5 | 179.1 | 132.5 | 135.6 |
| Accrued liabilities | 375.9 | 329.9 | 237.1 | 210.3 |
| Deferred revenue | — | — | — | — |
| Total current liabilities | 598.5 | 529.0 | 369.6 | 565.2 |
| Total debt | 1,296.8 | 1,329.5 | 466.2 | 259.3 |
| Total liabilities | 2,342.8 | 2,154.4 | 1,088.6 | 823.4 |
| Equity | ||||
| Retained earnings | (1,467.5) | (283.0) | 542.5 | 575.7 |
| Total shareholders' equity | 1,491.9 | 2,564.3 | 3,420.7 | 3,449.8 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?